Diabetic Retinopathy: Can a Simple Blood Test Predict Your Risk?
"New research explores how microRNA-211 could be a game-changing biomarker for early detection and treatment of diabetic retinopathy."
Diabetic retinopathy (DR) is a serious eye condition that can lead to blindness. It's a complication of diabetes, affecting the small blood vessels in the retina. Imagine your eyesight gradually fading because of something that might be preventable! DR is a leading cause of vision loss worldwide, but early detection and treatment can make a huge difference.
Excitingly, new research is shedding light on how we might better predict and manage this condition. Scientists have been studying microRNAs (miRNAs), tiny molecules that play a big role in controlling how our genes work. These miRNAs are involved in many processes in the body, including those related to diabetes and its complications.
One particular miRNA, called miR-211, has shown promise as a biomarker for DR. A biomarker is something in the body that can indicate a disease or condition. The goal of a recent study was to see if miR-211, found in blood samples, could help identify people at risk of developing DR or those who already have it.
The Ongoing Burden of Diabetic Retinopathy
Diabetic retinopathy is a leading cause of vision loss for working-age adults and occurs when chronically high blood sugar damages small retinal blood vessels. The CDC's Vision and Eye Health Surveillance System (VEHSS) uses Bayesian meta-regression to combine multiple data sources and produce modeled estimates of diabetic retinopathy prevalence among the entire U.S. population in 2021. Early screening, glycaemic and blood pressure control, timely treatment, patient education, and regular monitoring remain central to reducing vision loss.
From Classification to Laser Treatment
The history of diabetic retinopathy includes diagnostic advances such as fluorescein angiography, ultrasound examination, and optical coherence tomography. In 1890, Julius Hirschberg classified diabetic retinopathy into four types, describing its natural history. Later, the Early Treatment Diabetic Retinopathy Study was a multicenter randomized clinical trial that examined laser treatment for early diabetic eye disease and reported reduced progression in the majority of patients.
What the Researchers Did
The research team conducted a thorough study involving patients with and without diabetes. They divided the participants into three groups: healthy controls, individuals with diabetes but no DR, and individuals with diabetic retinopathy. The team collected blood samples from all participants and analyzed them to measure the levels of different miRNAs.
- miRNA microarray analysis
- Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
- Receiver operating characteristic curve
Blood-Based Biomarkers Remain Under Investigation
Current standards recommend that people with type 2 diabetes receive an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist at the time of diagnosis. Reviews of diabetic retinopathy research examine its epidemiology, pathophysiology, management strategies, and emerging therapeutic approaches. However, a study of circulating microRNAs reported that none of the studied microRNAs had sufficient diagnostic potential for diabetic retinopathy.
Why MicroRNA Tests Are Not Ready
A Scientific Reports study found its plasma microRNA results encouraging but emphasized that they came from a small cohort. The authors said independent, multicentric, and prospective studies are needed to validate diagnostic performance before these biomarkers enter clinical practice or alter management protocols. A separate review noted that many studies are retrospective case-control investigations and that the lack of consensus on uniform, stable internal reference genes can produce inconsistent relative quantification results.
Blood Sugar Measures and Eye Screening
The National Eye Institute notes that a blood test can show a person's average blood sugar level over the past three months. That information differs from an eye examination, which is used to evaluate diabetic retinopathy directly. The NIDDK reports that finding and treating diabetic retinopathy early can reduce the risk of blindness by 95 percent, while research continues to compare health-system screening models and artificial intelligence-assisted screening with manual methods.
Why This Matters
This research is a significant step forward in understanding and managing diabetic retinopathy. Identifying miR-211 as a potential biomarker opens the door for developing a simple blood test to screen individuals at risk. Early detection means earlier intervention and treatment, which can prevent or delay vision loss. While more research is needed to confirm these findings, the future looks promising for better diagnosis and care for those with diabetes.
Vision Requires More Than Acuity Testing
Visual function impairment from diabetic retinopathy can considerably affect quality of life. Best-corrected visual acuity is the most commonly used measure for assessing visual function and guiding clinical trials. Expert commentary notes that visual acuity can be affected late in the disease, may not reflect early disease, and does not capture some visual disturbances reported by patients.
A Global Health Challenge
Diabetic retinopathy can lead to vision-threatening complications in people living with diabetes mellitus, and decades of research have expanded understanding of its progression from non-proliferative to proliferative disease. It remains a major ocular complication of diabetes with significant global health impact. Advances in optical coherence tomography, imaging access, and anti-VEGF treatment have changed management, but the condition continues to carry substantial public-health implications.
Progression Can Change Lives
A prospective longitudinal U.S. cohort study published in 2025 examined how diabetic retinopathy severity affects the risk of progression to proliferative diabetic retinopathy or clinically significant macular edema. A Liverpool Diabetic Eye Study report cited in a case report found a 0.3% incidence of sight-threatening diabetic retinopathy among patients without retinopathy at diabetes diagnosis. The same case report described a patient who lost vision in the left eye within five years because of diabetic retinopathy, illustrating the potential personal consequences of progression.